Anti-radiation Drugs Market (Compound: Potassium Iodide, Prussian Blue, DTPA, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
Anti-Radiation Drugs Market – Scope of Report
TMR’s report on the global anti-radiation drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global anti-radiation drugs market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global anti-radiation drugs market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the anti-radiation drugs market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global anti-radiation drugs market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global anti-radiation drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global anti-radiation drugs market.
The report delves into the competitive landscape of the global anti-radiation drugs market. Key players operating in the global anti-radiation drugs market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global anti-radiation drugs market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market anti-radiation drugs.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
- 1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
- 2. Assumptions and Research Methodology
- 3. Executive Summary: Global Anti-radiation Drugs Market
- 4. Market Overview
- 4.1. Introduction
- 4.1.1. Definition
- 4.1.2. Industry Evolution/Developments
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Anti-radiation Drugs Market Analysis and Forecast, 2017–2031
- 5. Key Insights
- 5.1. Pipeline Analysis
- 5.2. Key Industry Events (Partnership, Investment, Merger & Acquisition, etc.)
- 5.3. Insights on Radiation Pills
- 5.4. Regulatory Scenario, by Key Region/ Country
- 5.5. COVID-19 Impact Analysis
- 6. Global Anti-radiation Drugs Market Analysis and Forecast, by Compound
- 6.1. Introduction & Definition
- 6.2. Market Value Forecast, by Compound, 2017–2031
- 6.2.1. Potassium Iodide (KI)
- 6.2.2. Prussian Blue
- 6.2.3. DTPA (Diethylenetriamine Pentaacetate)
- 6.2.4. Others
- 6.3. Market Attractiveness, by Compound
- 7. Global Anti-radiation Drugs Market Analysis and Forecast, by Application
- 7.1. Introduction & Definition
- 7.2. Market Value Forecast, by Application, 2017–2031
- 7.2.1. Acute Radiation Syndrome (ARS)
- 7.2.2. Cancer Treatment
- 7.2.3. Radiation Exposure
- 7.2.4. Others
- 7.3. Market Attractiveness Analysis, by Application
- 8. Global Anti-radiation Drugs Market Analysis and Forecast, by Distribution Channel
- 8.1. Introduction & Definition
- 8.2. Market Value Forecast, by Distribution Channel, 2017–2031
- 8.2.1. Hospital Pharmacies
- 8.2.2. Retail Pharmacies
- 8.2.3. Others
- 8.3. Market Attractiveness Analysis, by Distribution Channel
- 9. Global Anti-radiation Drugs Market Analysis and Forecast, by Region
- 9.1. Key Findings
- 9.2. Market Value Forecast, by Region
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
- 9.3. Market Attractiveness Analysis, by Region
- 10. North America Anti-radiation Drugs Market Analysis and Forecast
- 10.1. Introduction
- 10.1.1. Key Findings
- 10.2. Market Value Forecast, by Compound, 2017–2031
- 10.2.1. Potassium Iodide (KI)
- 10.2.2. Prussian Blue
- 10.2.3. DTPA (Diethylenetriamine Pentaacetate)
- 10.2.4. Others
- 10.3. Market Value Forecast, by Application, 2017–2031
- 10.3.1. Acute Radiation Syndrome (ARS)
- 10.3.2. Cancer Treatment
- 10.3.3. Radiation Exposure
- 10.3.4. Others
- 10.4. Market Value Forecast, by Distribution Channel, 2017–2031
- 10.4.1. Hospital Pharmacies
- 10.4.2. Retail Pharmacies
- 10.4.3. Others
- 10.5. Market Value Forecast, by Country, 2017–2031
- 10.5.1. U.S.
- 10.5.2. Canada
- 10.6. Market Attractiveness Analysis
- 10.6.1. By Compound
- 10.6.2. By Application
- 10.6.3. By Distribution Channel
- 10.6.4. By Country
- 11. Europe Anti-radiation Drugs Market Analysis and Forecast
- 11.1. Introduction
- 11.1.1. Key Findings
- 11.2. Market Value Forecast, by Compound, 2017–2031
- 11.2.1. Potassium Iodide (KI)
- 11.2.2. Prussian Blue
- 11.2.3. DTPA (Diethylenetriamine Pentaacetate)
- 11.2.4. Others
- 11.3. Market Value Forecast, by Application, 2017–2031
- 11.3.1. Acute Radiation Syndrome (ARS)
- 11.3.2. Cancer Treatment
- 11.3.3. Radiation Exposure
- 11.3.4. Others
- 11.4. Market Value Forecast, by Distribution Channel, 2017–2031
- 11.4.1. Hospital Pharmacies
- 11.4.2. Retail Pharmacies
- 11.4.3. Others
- 11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
- 11.5.1. Germany
- 11.5.2. U.K.
- 11.5.3. France
- 11.5.4. Spain
- 11.5.5. Italy
- 11.5.6. Rest of Europe
- 11.6. Market Attractiveness Analysis
- 11.6.1. By Compound
- 11.6.2. By Application
- 11.6.3. By Distribution Channel
- 11.6.4. By Country/Sub-region
- 12. Asia Pacific Anti-radiation Drugs Market Analysis and Forecast
- 12.1. Introduction
- 12.1.1. Key Findings
- 12.2. Market Value Forecast, by Compound, 2017–2031
- 12.2.1. Potassium Iodide (KI)
- 12.2.2. Prussian Blue
- 12.2.3. DTPA (Diethylenetriamine Pentaacetate)
- 12.2.4. Others
- 12.3. Market Value Forecast, by Application, 2017–2031
- 12.3.1. Acute Radiation Syndrome (ARS)
- 12.3.2. Cancer Treatment
- 12.3.3. Radiation Exposure
- 12.3.4. Others
- 12.4. Market Value Forecast, by Distribution Channel, 2017–2031
- 12.4.1. Hospital Pharmacies
- 12.4.2. Retail Pharmacies
- 12.4.3. Others
- 12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
- 12.5.1. China
- 12.5.2. Japan
- 12.5.3. India
- 12.5.4. Australia & New Zealand
- 12.5.5. Rest of Asia Pacific
- 12.6. Market Attractiveness Analysis
- 12.6.1. By Compound
- 12.6.2. By Application
- 12.6.3. By Distribution Channel
- 12.6.4. By Country/Sub-region
- 13. Latin America Anti-radiation Drugs Market Analysis and Forecast
- 13.1. Introduction
- 13.1.1. Key Findings
- 13.2. Market Value Forecast, by Compound, 2017–2031
- 13.2.1. Potassium Iodide (KI)
- 13.2.2. Prussian Blue
- 13.2.3. DTPA (Diethylenetriamine Pentaacetate)
- 13.2.4. Others
- 13.3. Market Value Forecast, by Application, 2017–2031
- 13.3.1. Acute Radiation Syndrome (ARS)
- 13.3.2. Cancer Treatment
- 13.3.3. Radiation Exposure
- 13.3.4. Others
- 13.4. Market Value Forecast, by Distribution Channel, 2017–2031
- 13.4.1. Hospital Pharmacies
- 13.4.2. Retail Pharmacies
- 13.4.3. Others
- 13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
- 13.5.1. Brazil
- 13.5.2. Mexico
- 13.5.3. Rest of Latin America
- 13.6. Market Attractiveness Analysis
- 13.6.1. By Compound
- 13.6.2. By Application
- 13.6.3. By Distribution Channel
- 13.6.4. By Country/Sub-region
- 14. Middle East & Africa Anti-radiation Drugs Market Analysis and Forecast
- 14.1. Introduction
- 14.1.1. Key Findings
- 14.2. Market Value Forecast, by Compound, 2017–2031
- 14.2.1. Potassium Iodide (KI)
- 14.2.2. Prussian Blue
- 14.2.3. DTPA (Diethylenetriamine Pentaacetate)
- 14.2.4. Others
- 14.3. Market Value Forecast, by Application, 2017–2031
- 14.3.1. Acute Radiation Syndrome (ARS)
- 14.3.2. Cancer Treatment
- 14.3.3. Radiation Exposure
- 14.3.4. Others
- 14.4. Market Value Forecast, by Distribution Channel, 2017–2031
- 14.4.1. Hospital Pharmacies
- 14.4.2. Retail Pharmacies
- 14.4.3. Others
- 14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
- 14.5.1. GCC Countries
- 14.5.2. South Africa
- 14.5.3. Rest of Middle East & Africa
- 14.6. Market Attractiveness Analysis
- 14.6.1. By Compound
- 14.6.2. By Application
- 14.6.3. By Distribution Channel
- 14.6.4. By Country/Sub-region
- 15. Competition Landscape
- 15.1. Market Player - Competitive Matrix (by tier and size of companies)
- 15.2. Market Share Analysis, by Company (2021)
- 15.3. Company Profiles
- 15.3.1. Amgen Inc.
- 15.3.1.1. Company Overview
- 15.3.1.2. Compound Portfolio
- 15.3.1.3. SWOT Analysis
- 15.3.1.4. Financial Overview
- 15.3.1.5. Strategic Overview
- 15.3.2. Anbex Inc.
- 15.3.2.1. Company Overview
- 15.3.2.2. Compound Portfolio
- 15.3.2.3. SWOT Analysis
- 15.3.2.4. Financial Overview
- 15.3.2.5. Strategic Overview
- 15.3.3. Arco Pharmaceuticals LLC
- 15.3.3.1. Company Overview
- 15.3.3.2. Compound Portfolio
- 15.3.3.3. SWOT Analysis
- 15.3.3.4. Financial Overview
- 15.3.4. BTG International Inc.
- 15.3.4.1. Company Overview
- 15.3.4.2. Compound Portfolio
- 15.3.4.3. SWOT Analysis
- 15.3.4.4. Financial Overview
- 15.3.4.5. Strategic Overview
- 15.3.5. Cellphire, Inc.
- 15.3.5.1. Company Overview
- 15.3.5.2. Compound Portfolio
- 15.3.5.3. SWOT Analysis
- 15.3.5.4. Financial Overview
- 15.3.5.5. Strategic Overview
- 15.3.6. Chrysalis BioTherapeutics, Inc.
- 15.3.6.1. Company Overview
- 15.3.6.2. Compound Portfolio
- 15.3.6.3. SWOT Analysis
- 15.3.7. Darnitsa
- 15.3.7.1. Company Overview
- 15.3.7.2. Compound Portfolio
- 15.3.7.3. SWOT Analysis
- 15.3.7.4. Strategic Overview
- 15.3.8. Enzychem Lifesciences Corporation
- 15.3.8.1. Company Overview
- 15.3.8.2. Compound Portfolio
- 15.3.8.3. SWOT Analysis
- 15.3.8.4. Strategic Overview
- 15.3.9. Humanetics Corporation
- 15.3.9.1. Company Overview
- 15.3.9.2. Compound Portfolio
- 15.3.9.3. SWOT Analysis
- 15.3.9.4. Financial Overview
- 15.3.9.5. Strategic Overview
- 15.3.10. Mission Pharmacal Company
- 15.3.10.1. Company Overview
- 15.3.10.2. Compound Portfolio
- 15.3.10.3. SWOT Analysis
- 15.3.10.4. Financial Overview
- 15.3.10.5. Strategic Overview
- 15.3.11. Myelo Therapeutics GmbH
- 15.3.11.1. Company Overview
- 15.3.11.2. Compound Portfolio
- 15.3.11.3. SWOT Analysis
- 15.3.11.4. Financial Overview
- 15.3.11.5. Strategic Overview
- 15.3.12. Partner Therapeutics
- 15.3.12.1. Company Overview
- 15.3.12.2. Compound Portfolio
- 15.3.12.3. SWOT Analysis
- 15.3.12.4. Financial Overview
- 15.3.12.5. Strategic Overview
- 15.3.13. Pluri Inc.
- 15.3.13.1. Company Overview
- 15.3.13.2. Compound Portfolio
- 15.3.13.3. SWOT Analysis
- 15.3.13.4. Financial Overview
- 15.3.13.5. Strategic Overview
- 15.3.14. Other Players
- 15.3.14.1. Company Overview
- 15.3.14.2. Compound Portfolio
- 15.3.14.3. SWOT Analysis
- 15.3.14.4. Financial Overview
- 15.3.14.5. Strategic Overview
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook